EA201300297A1 - LIQUID ANTI-VIRUS MEDICINE - Google Patents

LIQUID ANTI-VIRUS MEDICINE

Info

Publication number
EA201300297A1
EA201300297A1 EA201300297A EA201300297A EA201300297A1 EA 201300297 A1 EA201300297 A1 EA 201300297A1 EA 201300297 A EA201300297 A EA 201300297A EA 201300297 A EA201300297 A EA 201300297A EA 201300297 A1 EA201300297 A1 EA 201300297A1
Authority
EA
Eurasian Patent Office
Prior art keywords
buffer
inf
stabilizer
alpha
liquid drug
Prior art date
Application number
EA201300297A
Other languages
Russian (ru)
Other versions
EA021610B1 (en
Inventor
Илья Александрович МАРКОВ
Елена Алексеевна МАРКОВА
Полина Петровна ГАПОНЮК
Инна Николаевна МАРКОВА
Петр Яковлевич Гапонюк
Original Assignee
Илья Александрович МАРКОВ
Елена Алексеевна МАРКОВА
Полина Петровна ГАПОНЮК
Инна Николаевна МАРКОВА
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Илья Александрович МАРКОВ, Елена Алексеевна МАРКОВА, Полина Петровна ГАПОНЮК, Инна Николаевна МАРКОВА filed Critical Илья Александрович МАРКОВ
Priority to EA201300297A priority Critical patent/EA021610B1/en
Publication of EA201300297A1 publication Critical patent/EA201300297A1/en
Publication of EA021610B1 publication Critical patent/EA021610B1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к областям фармакологии и медицины и обеспечивает жидкое лекарственное средство, содержащее в качестве активного вещества ковалентный конъюгат интерферона-альфа (ИНФ-α) с полиэтиленгликолем (ПЭГ), буфер, стабилизатор и фармацевтически приемлемый растворитель, в котором ковалентный конъюгат является линейным или разветвлённым монопегилированным ИНФ-α общей формулы (I) или (II), стабилизатором является смесь сорбита, полисорбата 20 и L-глутамата натрия, буфером является цитратно-фосфатный буфер и фармацевтически приемлемым растворителем является вода. Техническим результатом изобретения является долговременная стабильность жидкого лекарственного средства с сохранением существенной доли активности немодифицированного интерферона-альфа, длительной циркуляцией в кровотоке и улучшенными характеристиками противовирусной активности и иммуногенности при хранении.The invention relates to the fields of pharmacology and medicine and provides a liquid drug containing as an active substance the covalent conjugate of interferon-alpha (INF-α) with polyethylene glycol (PEG), a buffer, a stabilizer and a pharmaceutically acceptable solvent, in which the covalent conjugate is linear or branched monopegylated INF-α of the general formula (I) or (II), the stabilizer is a mixture of sorbitol, polysorbate 20 and sodium L-glutamate, the buffer is citrate-phosphate buffer and pharmaceutically intake Solvent is water. The technical result of the invention is the long-term stability of the liquid drug with the preservation of a significant proportion of the activity of unmodified interferon-alpha, prolonged circulation in the bloodstream and improved characteristics of antiviral activity and immunogenicity during storage.

EA201300297A 2013-03-28 2013-03-28 Liquid antiviral formulation EA021610B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA201300297A EA021610B1 (en) 2013-03-28 2013-03-28 Liquid antiviral formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA201300297A EA021610B1 (en) 2013-03-28 2013-03-28 Liquid antiviral formulation

Publications (2)

Publication Number Publication Date
EA201300297A1 true EA201300297A1 (en) 2014-09-30
EA021610B1 EA021610B1 (en) 2015-07-30

Family

ID=51628523

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201300297A EA021610B1 (en) 2013-03-28 2013-03-28 Liquid antiviral formulation

Country Status (1)

Country Link
EA (1) EA021610B1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2101918A1 (en) * 1991-03-18 1992-09-19 Samuel Zalipsky Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US8003117B2 (en) * 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
MXPA05010411A (en) * 2003-03-28 2006-05-31 Biopolymed Inc Biologically active material conjugated with biocompatible polymer with 1:1 complex, preparation method thereof and pharmaceutical composition comprising the same.
WO2009030066A1 (en) * 2007-09-04 2009-03-12 Biosteed Gene Expression Tech. Co., Ltd. Polyethylene glycol modified interferon alpha 2b and preparation method and applicatioins thereof
RU2447083C1 (en) * 2010-07-20 2012-04-10 Закрытое Акционерное Общество "Биокад" NOVEL FUNCTIONALLY ACTIVE, HIGHLY PURE, STABLE CONJUGATE OF INTERFERON α WITH POLYETHYLENE GLYCOL, REPRESENTED BY ONE PEG- NαH-IFN POSITIONAL ISOMER, WITH IMPROVED IMMUNOGENICITY, WITH PROLONGED BIOLOGICAL ACTION, SUITABLE FOR MEDICAL APPLICATION, AND IMMUNOLOGICAL AGENT BASED THEREON
RU2433135C1 (en) * 2010-10-06 2011-11-10 Общество с ограниченной ответственностью "ФОРТ" Interferon conjugated with polyethylene glycol

Also Published As

Publication number Publication date
EA021610B1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
CY1123597T1 (en) INSULIN PREPARATION FOR QUICK RECRUITMENT
CY1122516T1 (en) READY-TO-USE FORMULATIONS OF KETOROLAK
CU23734A1 (en) IMMUNOMODULATOR POLIPEPTIDES DERIVED FROM IL-2 WITH ANTIGONIST ACTIVITY OF THIS CITOCINE USED IN CANCER THERAPY AND CHRONIC INFECTIOUS DISEASES
AR068816A1 (en) COMPOSITIONS OF BRIMONIDINE IMPROVED FOR THE TREATMENT OF ERYTHEMA
RU2016113283A (en) Liquid protein formulations containing viscosity reducers
EA201492021A1 (en) ANTI-COMPOSITION
CU23923B1 (en) POLYPEPTIDES DERIVED FROM IL-2 WITH AGONIST ACTIVITY
BR112015011179A8 (en) stable aqueous pharmaceutical compositions comprising human insulin or an analogue or derivative thereof, their use and processes for their preparation
JP2016539921A5 (en)
RU2010129824A (en) NEW functionally active, highly purified, stable Alpha interferon conjugate with polyethylene glycol, represented by one of positional isomers of PEG-IFN-NAH with reduced immunogenicity, with a prolonged biological effect are suitable for medical applications, and immunobiological agent based on ITS
RU2016139373A (en) Slow-Release Buprenorphine Solutions
IN2014MN01470A (en)
PE20140134A1 (en) METHODS TO IMPROVE OXYGENATION OF ENDANGERED TISSUE
CO7151496A2 (en) Therapeutic agents for optimized subcutaneous administration
HRP20201696T1 (en) Pharmaceutical parenteral formulation containing carglumic acid
CR20220546A (en) Drug for treating coronaviral and retroviral infections and hepatitis c
EA201300297A1 (en) LIQUID ANTI-VIRUS MEDICINE
RU2013146452A (en) INJECTION OR INFUSION TRIAZAVIRINE SOLUTION FOR TREATING VIRAL INFECTIONS
NZ731518A (en) Formulations of a pi3k/mtor-inhibitor for intravenous administration
RU2010114841A (en) SELF-CONTAINING DRUG FOR PREVENTION AND TREATMENT OF MICROELEMENTOSIS IN AGRICULTURAL ANIMALS AND BIRDS
AR082806A1 (en) STABLE PHARMACEUTICAL COMPOSITION
EA201491841A1 (en) COMPOSITION OF ESMOLOL FOR PARENTERAL INTRODUCTION
EA201101663A1 (en) COVALENT CONJUGATE OF POLYETHYLENE GLYCOL WITH GRANULOCITARIAN COLONIUS STIMULATING FACTOR OF THE PERSON
RU2020109402A (en) GLP-1 BASED COMPOSITIONS AND WAYS OF THEIR APPLICATION
BR112017012975A2 (en) injectable paracetamol formulations

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG TJ TM